Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 16.03.2026 3 Am J Gastroenterol 2 Biochem Biophys Res Commun 2 BMC Cancer 1 BMC Gastroenterol 1 Cancer 12 Clin Res Hepatol Gastroenterol 7 Dig Dis Sci 3 Endoscopy 2 Eur J Pediatr 3 Eur Radiol 2 Gastroenterology 1 Gastrointest Endosc 1 Gut 3 Hepatology 3 Indian J Gastroenterol 1 Int J Cancer 1 J Comput Assist Tomogr 2 J Gastroenterol 8 J Gastroenterol Hepatol 10 J Hepatol 1 J Pediatr Surg 7 PLoS One 2 Radiol Imaging Cancer 2 Radiology 5 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. BARRITT AS 4TH, Tapper EB, Newsome PN, Gazis D, et al
   Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
   Am J Gastroenterol. 2026;121:710-719.
   PubMed         Abstract available
   
   
2. JOHN BV, Bastaich D, Marchetti D, Perumalswami P, et al
   Association of Glucagon-Like Peptide-1 Receptor Agonists With Liver-Related Outcomes and All-Cause Mortality in Patients With Harmful Alcohol Use: A Target Trial Emulation Study.
   Am J Gastroenterol. 2026;121:697-709.
   PubMed         Abstract available
   
   
3. SILVEY S, Patel N, Tsai SY, Nadeem M, et al
   Correction to Higher Rate of Spontaneous Bacterial Peritonitis Recurrence With Secondary Spontaneous Bacterial Peritonitis Prophylaxis Compared With No Prophylaxis in 2 National Cirrhosis Cohorts.
   Am J Gastroenterol. 2026 Mar 9. doi: 10.14309/ajg.0000000000003941.
   PubMed        
   
   

   
   Biochem Biophys Res Commun

4. CHEN D, Dong X, Chen D, Lin J, et al
   Cdh1 plays a protective role in nonalcoholic fatty liver disease by regulating PPAR/PGC-1alpha signaling pathway.
   Biochem Biophys Res Commun. 2023;681:13-19.
   PubMed         Abstract available
   
   
5. LI N, Sun Y, Ouyang J, Che Y, et al
   A TiN-based nanophotosensitizer for enhanced photothermal therapy with the aid of ultrasound.
   Biochem Biophys Res Commun. 2023;679:82-89.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. WAN J, Jin C, Fan Z, Yu C, et al
   Clinical efficacy of HAIC combined with TACE in patients with unresectable intrahepatic cholangiocarcinoma.
   BMC Cancer. 2026 Mar 11. doi: 10.1186/s12885-026-15822.
   PubMed        
   
   
7. GUO J, Tang H, Xu T, Zhang Y, et al
   Development and validation of a SHAP-explainable preoperative predictive model for microvascular invasion in hepatocellular carcinoma.
   BMC Cancer. 2026 Mar 10. doi: 10.1186/s12885-026-15839.
   PubMed        
   
   

   
   BMC Gastroenterol

8. COURET A, Rannou F, Pereira B, Duclos M, et al
   Systematic review of prognostic value of cardiorespiratory fitness in patients with cirrhosis.
   BMC Gastroenterol. 2026 Mar 11. doi: 10.1186/s12876-026-04715.
   PubMed         Abstract available
   
   

   
   Cancer

9. CHEN Q, Wang X, Zheng Y, Ye T, et al
   Cancer-associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD-1 inhibitors and antiangiogenic agents in hepatocellular carcinoma.
   Cancer. 2023;129:3405-3416.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

10. HOUNTONDJI L, Pureur D, Chabannes M, Felix S, et al
    Transjugular Intrahepatic Portosystemic Shunt is effective to treat portal hypertension due to sinusoidal obstructive syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102201.
    PubMed         Abstract available
    
    
11. RENAULT T, Meunier L, Monet C
    Acute liver failure following immune checkpoint inhibitors.
    Clin Res Hepatol Gastroenterol. 2023;47:102203.
    PubMed         Abstract available
    
    
12. BEDEWY A, El-Kassas M
    Anesthesia in patients with chronic liver disease: An updated review.
    Clin Res Hepatol Gastroenterol. 2023;47:102205.
    PubMed         Abstract available
    
    
13. KOUNIS I, Sacleux SC, Ordan MA, Andre S, et al
    Efficiency and safety of total plasma exchange in critically ill cirrhotic patients with acute on chronic liver failure: A pilot study.
    Clin Res Hepatol Gastroenterol. 2023;47:102206.
    PubMed         Abstract available
    
    
14. CAO Q, Chen S, Zhang Y, Yang J, et al
    Clinical characteristics and risk factors of drug-induced hepatotoxicity in cancer patients following repeated chemotherapy cycles.
    Clin Res Hepatol Gastroenterol. 2026;50:102763.
    PubMed         Abstract available
    
    
15. DONGIER A, Louis E, Loly JP, Dandoy P, et al
    QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.
    Clin Res Hepatol Gastroenterol. 2026 Jan 26:102776.
    PubMed         Abstract available
    
    
16. LOHO IM, Hasan I, Gani RA, Harimurti K, et al
    Development of the MANTAP score for predicting one-year mortality in intermediate-stage hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2026;50:102781.
    PubMed         Abstract available
    
    
17. THOMPSON K, Breaux W, Miller LS, Nemeth J, et al
    Effect of common diabetes medications on metabolic dysfunction-associated steatotic liver disease as measured by transient elastography and other metabolic parameters: A systematic review.
    Clin Res Hepatol Gastroenterol. 2026;50:102784.
    PubMed         Abstract available
    
    
18. CHEN Y, Yang X, Li X
    Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study.
    Clin Res Hepatol Gastroenterol. 2023;47:102196.
    PubMed         Abstract available
    
    
19. DUMORTIER J, Erard D, Villeret F, Faitot F, et al
    Bariatric surgery and liver transplantation, here we are now: A French nationwide retrospective study.
    Clin Res Hepatol Gastroenterol. 2023;47:102164.
    PubMed         Abstract available
    
    
20. LALLEMENT A, Lamoureux A, Hummelsberger M, Maria A, et al
    Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: Case report and review of literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102192.
    PubMed         Abstract available
    
    
21. LIU Y, Sun M
    An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102195.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

22. ZHANG W, Hu H
    The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Dig Dis Sci. 2026;71:852-867.
    PubMed         Abstract available
    
    
23. NASIR AB, Alkhouri N, Gish R, Jain AK, et al
    Advancing the Diagnosis and Management of Genetic Cholestatic Liver Disease in Adults.
    Dig Dis Sci. 2025 Oct 9. doi: 10.1007/s10620-025-09431.
    PubMed         Abstract available
    
    
24. MEGURO J, Huber M, Goldberg D
    State-Level Variability in Location of Death of Patients with End-Stage Liver Disease.
    Dig Dis Sci. 2026;71:933-940.
    PubMed         Abstract available
    
    
25. BHARADWAJ HR, Dahiya DS, Dalal P, Fuad M, et al
    Inequalities in Gastrointestinal Care Provision in the United Kingdom.
    Dig Dis Sci. 2026;71:822-837.
    PubMed         Abstract available
    
    
26. TIAN X, Wang Y, Yuan M, Zheng W, et al
    Heme Oxygenase-1-Modified BMMSCs Activate AMPK-Nrf2-FTH1 to Reduce Severe Steatotic Liver Ischemia-Reperfusion Injury.
    Dig Dis Sci. 2023;68:4196-4211.
    PubMed         Abstract available
    
    
27. WU YT, Li QZ, Zhao XK, Mu M, et al
    Anlotinib Attenuates Liver Fibrosis by Regulating the Transforming Growth Factor beta1/Smad3 Signaling Pathway.
    Dig Dis Sci. 2023;68:4186-4195.
    PubMed         Abstract available
    
    
28. SPANN A, Louissaint J
    Advancing Advance Directive Completion Rates in Patients with Decompensated Cirrhosis.
    Dig Dis Sci. 2026 Mar 11. doi: 10.1007/s10620-026-09815.
    PubMed        
    
    

    
    Endoscopy

29. PIZZICANNELLA M, Ligresti D, Rancatore G, Quintini D, et al
    Endoscopic ultrasound-guided treatment for non-stenotic cholangitis in transplant recipient with hepaticojejunal anastomosis.
    Endoscopy. 2026;58.
    PubMed        
    
    
30. TAKENAKA M, Kawamoto H, Fukunaga T, Sakano Y, et al
    The usefulness of the novel 0.018-inch dedicated uneven double-lumen cannula for endoscopic ultrasound-guided hepaticogastrostomy using a 22-gauge needle.
    Endoscopy. 2026;58.
    PubMed        
    
    
31. NAKAMURA J, Ogura T, Bessho K, Trong NN, et al
    Bridging multi-hole self-expandable metal stent deployment for hepatic hilar obstruction under endoscopic ultrasound guidance.
    Endoscopy. 2026;58.
    PubMed        
    
    

    
    Eur J Pediatr

32. YANG P, Wang G, Guo J, Yan W, et al
    A nomogram for predicting Kawasaki Disease in acutely febrile children with liver injury.
    Eur J Pediatr. 2026;185:157.
    PubMed         Abstract available
    
    
33. YANG P, Mao Z, Sun M, Guo J, et al
    Clinical features analysis of Kawasaki disease with abdominal symptoms as the first manifestation.
    Eur J Pediatr. 2023;182:4049-4057.
    PubMed         Abstract available
    
    

    
    Eur Radiol

34. FERRAIOLI G, Roccarina D, Kumada T, Ogawa S, et al
    Optimization of measurements with an ultrasound attenuation coefficient algorithm for quantifying liver fat.
    Eur Radiol. 2026;36:1853-1863.
    PubMed         Abstract available
    
    
35. MARTI-AGUADO D, Alfaro-Cervello C, Fernandez-Paton M, Ten-Esteve A, et al
    Digital pathology and lipid droplet size as a key determinant of discrepancies between histology and MRI gradings in steatotic liver disease.
    Eur Radiol. 2026;36:1050-1060.
    PubMed         Abstract available
    
    
36. ERLEY J, Breckow J, Roedl K, Ozga AK, et al
    Dual-energy CT liver fat fraction as prognostic imaging biomarker in critically ill patients.
    Eur Radiol. 2026;36:1341-1350.
    PubMed         Abstract available
    
    

    
    Gastroenterology

37. ALBRECHT T, Rossberg A, Albrecht JD, Nicolay JP, et al
    Deep Learning-Enabled Diagnosis of Liver Adenocarcinoma.
    Gastroenterology. 2023;165:1262-1275.
    PubMed         Abstract available
    
    
38. SARIN SK, Tripathti DM, Lohse AW
    Non-cirrhotic Portal Fibrosis, Idiopathic Portal Hypertension and Porto-sinusoidal Vascular Diseases: From Debates to Future Directions.
    Gastroenterology. 2026 Mar 10:S0016-5085(26)00199.
    PubMed        
    
    

    
    Gastrointest Endosc

39. SARKIS Y, Masuoka H, Ghabril M, Gutta A, et al
    EUS-guided treatment of bleeding peristomal varices (with video).
    Gastrointest Endosc. 2023;98:843-847.
    PubMed         Abstract available
    
    

    
    Gut

40. HUO Z, Chen Y, Huang Y, Yang Z, et al
    Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts.
    Gut. 2026;75:772-785.
    PubMed         Abstract available
    
    

    
    Hepatology

41. HERMAN-SANCHEZ N, Fernandez-Barrena MG, Alanon-Martinez PE, Uriarte I, et al
    Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through non-canonical SAGA-MYC signalling modulation.
    Hepatology. 2026 Mar 6. doi: 10.1097/HEP.0000000000001736.
    PubMed         Abstract available
    
    
42. YAN N, Xia Y, Zhang Y, Sawaswong V, et al
    Hepatocyte CEBPA-ORM1 axis restricts alcohol-associated liver disease.
    Hepatology. 2026 Mar 9. doi: 10.1097/HEP.0000000000001737.
    PubMed         Abstract available
    
    
43. WU J, Jiang Z, Li Q, Cheng CS, et al
    FYN/LCK kinase balance as a metabolic switch orchestrates progenitor exhausted T Cell differentiation in hepatocellular carcinoma.
    Hepatology. 2026 Mar 11. doi: 10.1097/HEP.0000000000001740.
    PubMed         Abstract available
    
    

    
    Indian J Gastroenterol

44. ASARI SB
    Letter to editor: Non-selective beta-blockers are well tolerated in pregnancy with portal hypertension.
    Indian J Gastroenterol. 2026 Mar 3. doi: 10.1007/s12664-026-01983.
    PubMed        
    
    
45. PREMARATNE BE, Bandara Tillakaratne S, Gunathilake MB, Dassanayake A, et al
    Clinicopathological profile of diabetic versus non-diabetic patients with MASLD-related hepatocellular carcinoma.
    Indian J Gastroenterol. 2026 Mar 7. doi: 10.1007/s12664-026-01978.
    PubMed        
    
    
46. ALEXANDER V, Goel A
    Response to correspondence on "Non-selective beta blockers are well tolerated in pregnancy with portal hypertension".
    Indian J Gastroenterol. 2026 Mar 8. doi: 10.1007/s12664-025-01960.
    PubMed        
    
    

    
    Int J Cancer

47. ZHANG X, Zhao L, Campbell PT, Chen Y, et al
    The impact of genetic and environmental risk factors on adverse liver outcomes.
    Int J Cancer. 2026;158:2317-2328.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

48. LIU HS, Chen CB, Wu KL, Chou CT, et al
    Assessment of Hepatic Fibrosis Through Radiomics Models Utilizing Diffusion-Based Virtual Magnetic Resonance Elastography.
    J Comput Assist Tomogr. 2026 Mar 10. doi: 10.1097/RCT.0000000000001832.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

49. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    PubMed         Abstract available
    
    
50. TADA F, Hiraoka A, Tada T, Hirooka M, et al
    Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
    J Gastroenterol. 2023;58:1134-1143.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

51. PARK HJ, Kim SY, Lim YS
    Updates in Abbreviated MRI-Based HCC Surveillance.
    J Gastroenterol Hepatol. 2026;41:914-926.
    PubMed         Abstract available
    
    
52. HSIEH ML, Su TH, Lin YC, Chen YY, et al
    Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1041-1051.
    PubMed         Abstract available
    
    
53. LI Y, Li J, Dullaart RPF, Moshage H, et al
    Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.
    J Gastroenterol Hepatol. 2026;41:880-894.
    PubMed         Abstract available
    
    
54. KWON YJ, Kim M, Heo SJ, Lee JW, et al
    Combined Impact of Triglyceride-Glucose Index and Alanine Aminotransferase on Steatotic Liver Disease and Subtypes.
    J Gastroenterol Hepatol. 2026;41:1030-1040.
    PubMed         Abstract available
    
    
55. BAE SK, Akamatsu N, Ichida A, Nishioka Y, et al
    High Intrahepatic cccDNA in Resolved HBV Infection: Insights From Living Donor Liver Transplantation With Anti-HBc-Positive Grafts.
    J Gastroenterol Hepatol. 2026 Mar 11. doi: 10.1111/jgh.70324.
    PubMed         Abstract available
    
    
56. ZHANG S, Wang W, Cai W, Zhong B, et al
    MR Radiomics Combined With Radiologic Features to Predict Recurrence Location in Nonviable Hepatocellular Carcinoma After Transarterial Chemoembolization.
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70325.
    PubMed         Abstract available
    
    
57. MUJAHID MUF, Haider E
    A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70328.
    PubMed        
    
    
58. O'HARA SP, Bogert PT, Dickinson S, Chen X, et al
    Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70279.
    PubMed         Abstract available
    
    

    
    J Hepatol

59. ZHAO J, Yang L, Qin Y, Zhang Y, et al
    Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression: Roles of AKT and YAP during iCCA.
    J Hepatol. 2026 Mar 4:S0168-8278(26)00119-4. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
60. NEUBER J, Lohrmann F, Wald S, Gocer M, et al
    Kupffer cell plasticity regulates hepatic immunity in mycobacterial infection: Kupffer cell plasticity.
    J Hepatol. 2026 Mar 4:S0168-8278(26)00118-2. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
61. VERMA S, Hingwala J, Low JTS, Patel AA, et al
    Palliative clinical trials in advanced chronic liver disease: Challenges and opportunities.
    J Hepatol. 2023;79:1236-1253.
    PubMed         Abstract available
    
    
62. WANG L, Zhu L, Liang C, Huang X, et al
    Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis.
    J Hepatol. 2023;79:1185-1200.
    PubMed         Abstract available
    
    
63. STAELS B, Butruille L, Francque S
    Treating NASH by targeting peroxisome proliferator-activated receptors.
    J Hepatol. 2023;79:1302-1316.
    PubMed         Abstract available
    
    
64. LI B, Yang Z, Mao F, Gong W, et al
    Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2.
    J Hepatol. 2023;79:1096-1109.
    PubMed         Abstract available
    
    
65. LU Y, Sun Q, Guan Q, Zhang Z, et al
    The XOR-IDH3alpha axis controls macrophage polarization in hepatocellular carcinoma.
    J Hepatol. 2023;79:1172-1184.
    PubMed         Abstract available
    
    
66. KUTER DJ, Bonkovsky HL, Monroy S, Ross G, et al
    Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.
    J Hepatol. 2023;79:1150-1158.
    PubMed         Abstract available
    
    
67. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
    Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
    PubMed         Abstract available
    
    
68. ADORINI L, Trauner M
    FXR agonists in NASH treatment.
    J Hepatol. 2023;79:1317-1331.
    PubMed         Abstract available
    
    

    
    J Pediatr Surg

69. MUNOZ-SERRANO AJ, Estefania-Fernandez K, Oterino C, Ramirez-Amoros C, et al
    Sarcopenia as a Prognostic Factor in Patients with Hepatoblastoma: Does It Influence Surgical Outcomes and Survival? Preliminary Retrospective Study.
    J Pediatr Surg. 2023;58:2149-2155.
    PubMed         Abstract available
    
    

    
    PLoS One

70. ZHANG S, Liu R, Li Z, Pan T, et al
    Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators.
    PLoS One. 2026;21:e0328952.
    PubMed         Abstract available
    
    
71. WANG Q, Guo J, Liu S, Cao X, et al
    Global, regional, and national burden of nonalcoholic fatty liver disease among adults aged >/= 45 years: A comprehensive analysis of epidemiological trends and projections to 2035.
    PLoS One. 2026;21:e0342697.
    PubMed         Abstract available
    
    
72. IBI Y, Omori T
    Cure rate estimation with insufficient follow-up: A median-based bootstrap correction approach.
    PLoS One. 2026;21:e0344669.
    PubMed         Abstract available
    
    
73. LI X, Min R
    Identification of core genes mediating the association between obesity and hepatocellular carcinoma: A bioinformatics study based on mitochondrial metabolism and immune pathways.
    PLoS One. 2026;21:e0344452.
    PubMed         Abstract available
    
    
74. DESALEGN MM, Fisseha H, Altaye MG, Berhane KA, et al
    Prevalence and associated factors of non-variceal upper gastrointestinal bleeding among cirrhotic patients with upper gastrointestinal bleeding on follow-up at a Tertiary Hospital in Ethiopia.
    PLoS One. 2026;21:e0343977.
    PubMed         Abstract available
    
    
75. YANG R, Xing L, Wang C, Zhang Y, et al
    Prognostic stratification in hepatocellular carcinoma using a telomerase-related lncRNA signature derived from TCGA database.
    PLoS One. 2026;21:e0339415.
    PubMed         Abstract available
    
    
76. LEI Y, Ma X, Jin X, He Y, et al
    Huanggan decoction ameliorates cholestatic hepatic fibrosis in rats via TGF-beta1/Smad3 signaling pathway.
    PLoS One. 2026;21:e0344168.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

77. SIDDIQI NS, Albuquerque J, Paolucci I, Lin YM, et al
    Quantifying Functional Liver Volume Loss after CT-guided Percutaneous Thermal Ablation: A COVER-ALL Trial Post Hoc Analysis.
    Radiol Imaging Cancer. 2026;8:e250385.
    PubMed         Abstract available
    
    
78. KHAVANDI MM, Crouch AC, Stolley DL, Seeley EH, et al
    Lipidomic Profiling of Rabbit VX2 Tumors Using Matrix-assisted Laser Desorption Ionization Mass Spectrometry Imaging.
    Radiol Imaging Cancer. 2026;8:e250588.
    PubMed         Abstract available
    
    

    
    Radiology

79. LI Y, Lu S, Mao S, Li Q, et al
    Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.
    Radiology. 2026;318:e252271.
    PubMed         Abstract available
    
    
80. CHOI ES, Koo B, Kim S, Song IH, et al
    MRI-based Risk Scoring System to Predict Early Recurrence after Resection of Solitary Hepatocellular Carcinoma 5 cm or Smaller.
    Radiology. 2026;318:e252611.
    PubMed         Abstract available
    
    

    
    Transplant Proc

81. TOSHIDA K, Toshima T, Itoh S, Yoshiya S, et al
    Caution to Poor Adherence With Immunosuppressant Medication That Causes Coma-Onset Autoimmune Encephalitis: A Case Report and Literature Review.
    Transplant Proc. 2023;55:1968-1971.
    PubMed         Abstract available
    
    
82. UEMOTO Y, Taura K, Yamada Y, Takeda H, et al
    A Rare Case of Donor-Origin Intrahepatic Cholangiocarcinoma After Liver Transplantation for Hepatocellular Carcinoma: A Case Report.
    Transplant Proc. 2023 Aug 5:S0041-1345(23)00472.
    PubMed         Abstract available
    
    
83. SHEN Y, Shi X, Zhang M, Xu Z, et al
    Liver Transplantation for Acute Liver Failure During Pregnancy: Case Report and Literature Review.
    Transplant Proc. 2023 Aug 24:S0041-1345(23)00483.
    PubMed         Abstract available
    
    
84. BOOTHANKAD SHARATH D, Shoucair S, Nadeem MA, Fujiki M, et al
    Case Report: Intra-abdominal Mucormycosis Diagnosed at the Time of Liver Transplantation for Surgically Induced Acute Liver Failure.
    Transplant Proc. 2026 Feb 2:S0041-1345(26)00040.
    PubMed         Abstract available
    
    
85. NICOLUZZI A, Goncalves LDC, Yamaoka LMM, Nicoluzzi JE, et al
    Liver Transplantation From a Recently Transplanted Multiorgan Patient: a Case Report.
    Transplant Proc. 2026 Feb 6:S0041-1345(26)00030.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum